Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Britt Stancil"'
Autor:
William Spreen, Britt Stancil, Kenneth H. Mayer, Miranda Murray, Alex R. Rinehart, Parul Patel, Robert M. Grant, Ian Frank, David A. Margolis, Martin Markowitz, Susan L. Ford, Krischan J Hudson
Publikováno v:
HIV Clinical Trials. 19:129-138
Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP).We report participant outcomes from the phase IIa ECLAIR study rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677b64c5ade40b356e2a389e4edf7407
https://doi.org/10.1080/15284336.2018.1511346
https://doi.org/10.1080/15284336.2018.1511346
Autor:
Robert L. Cuffe, Anna Christina. Grobler, David Dunn, Daniel Meyer, Britt Stancil, David V. Glidden, Brett Hanscom, Deborah Donnell, Amy Cutrell, Ronnie Wang
Publikováno v:
HIV clinical trials, vol 18, iss 5-6
Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-risk individuals from HIV-1 infection. Despite this record of effectiveness, concerns persist about the diminished protective effect observed in women compared wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f256a7156341f8adb90a013777d1b8c
https://doi.org/10.1080/15284336.2017.1379676
https://doi.org/10.1080/15284336.2017.1379676
Autor:
Hong Van Tieu, Ian Frank, Elizabeth Gould, Richard Elion, William Spreen, Winkler G. Weinberg, Magdalena E. Sobieszczyk, David A. Margolis, Susan L. Ford, Kimberly Y. Smith, Britt Stancil, Robert M. Grant, Chester Fisher, Kenneth H. Mayer, Deborah Goldstein, Joel E. Gallant, Parul Patel, Alex R. Rinehart, Krischan J Hudson, Martin Markowitz
Publikováno v:
The Lancet HIV. 4:e331-e340
Summary Background Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e5b62e6e7a0915cf0cacc9fb2be652
https://doi.org/10.1016/s2352-3018(17)30068-1
https://doi.org/10.1016/s2352-3018(17)30068-1
Autor:
David A. Margolis, Peter Williams, Anthony Mills, Britt Stancil, Marty St. Clair, William Spreen, Jean-Guy Baril, Edwin DeJesus, Jerome De Vente, Roger LeBlanc, Graham H.R. Smith, Kenneth Sutton
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB), an INI, is under development in both oral and long-acting (LA) injectable formulations. LATTE (NCT01641809) was designed to select a daily oral dose of CAB and evaluate a two-drug ART regimen with rilpivirine (RPV), as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::571ad3de378b3c6b0d3a4f42885630bc
http://europepmc.org/articles/PMC6809191
http://europepmc.org/articles/PMC6809191
Autor:
Trevor Hawkins, Shield Study Team, Britt Stancil, M H St Clair, Edwin DeJesus, Thanes Vanig, Belinda Ha, Benjamin Young
Publikováno v:
HIV Clinical Trials. 12:228-233
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c91b3f47d7f25522bb510701973c3d6
https://doi.org/10.1310/hct1204-228
https://doi.org/10.1310/hct1204-228
Autor:
Peter Williams, Krischan J Hudson, Susan L. Ford, Sandy Griffith, Melinda M Bomar, Marita Stevens, David A. Margolis, Marty St. Clair, Kimberly Y. Smith, Graham H R Smith, William Spreen, Debbie Hagins, Britt Stancil, Jerome De Vente, Cynthia Brinson, Joseph J. Eron
Publikováno v:
The Lancet. Infectious diseases. 15(10)
Summary Background In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine. We assessed cabotegr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff68214e260c6b5a0eca482280249c77
https://pubmed.ncbi.nlm.nih.gov/28750936
https://pubmed.ncbi.nlm.nih.gov/28750936
Autor:
Britt Stancil, Joseph J. Eron, Scott White, Edwin DeJesus, David A. Margolis, Paul Wannamaker, Mark Johnson
Publikováno v:
Antiviral therapy. 19(1)
Background Fosdevirine (GSK2248761) is a non-nucleoside reverse transcriptase inhibitor with HIV-1 activity against common efavirenz-resistant strains. Two partially blind, randomized, Phase IIb studies were initiated (1 in treatment-naive and 1 in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42ffebebeda854c90b526d1b1c0cce8
https://pubmed.ncbi.nlm.nih.gov/24158593
https://pubmed.ncbi.nlm.nih.gov/24158593
Autor:
Michael, Saag, Rukmini, Balu, Elizabeth, Phillips, Philip, Brachman, Claudia, Martorell, William, Burman, Britt, Stancil, Michael, Mosteller, Cindy, Brothers, Paul, Wannamaker, Arlene, Hughes, Denise, Sutherland-Phillips, Simon, Mallal, Mark, Shaefer, C, Zurawski
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 46(7)
Background. Although the human leukocyte antigen (HLA)–B*5701 is highly associated with a hypersensitivity reaction (HSR) to abacavir (ABC), variable sensitivities have been reported when clinical data alone have been used to define an ABC HSR. Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::443226908295192ef4da2763a6d7db33
https://pubmed.ncbi.nlm.nih.gov/18444831
https://pubmed.ncbi.nlm.nih.gov/18444831
Autor:
William Spreen, Michael Mosteller, Britt Stancil, A. D. Roses, A J Nelsen, S Hughes, Seth Hetherington, D E Thorborn, Arlene R Hughes, Eric H. Lai, Daniel K. Burns, Charles J. Cox, L L Warren
Publikováno v:
The pharmacogenomics journal. 8(6)
The hypersensitivity (HSR) to abacavir (ABC) pharmacogenetics (PGx) program represents the progression from an exploratory discovery to a validated biomarker. Within the program, two retrospective PGx studies were conducted to identify HIV-1 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bb99a78fc85ef47c15f65580c74cba9
https://pubmed.ncbi.nlm.nih.gov/18332899
https://pubmed.ncbi.nlm.nih.gov/18332899
Autor:
John, McHutchison, Zachary, Goodman, Keyur, Patel, Hala, Makhlouf, Maribel, Rodriguez-Torres, Mitchell, Shiffman, Don, Rockey, Petr, Husa, Wan-Long, Chuang, Robert, Levine, Mark, Jonas, Dickens, Theodore, Richard, Brigandi, Alison, Webster, Margaret, Schultz, Helen, Watson, Britt, Stancil, Stephen, Gardner, Sammy, Saab
Publikováno v:
Gastroenterology. 138:1365-1373.e2
Background & Aims Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor γ (PPARγ) and inhibits stellate cell activation. We evaluated its antifibrotic effect in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af9bdb87086b07f6d0e17596dbadde47
https://doi.org/10.1053/j.gastro.2009.12.003
https://doi.org/10.1053/j.gastro.2009.12.003